Asahi Kasei aims for global market through Phase III trials with novel anticoagulant
This article was originally published in Scrip
The diversified Japanese materials group Asahi Kasei is planning to take its recombinant human thrombomodulin-alfa product ART-123 into the global arena through the start of an international Phase III trial for the treatment of severe sepsis and coagulopathy.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.